Flavonoids and related compounds in non-alcoholic fatty liver disease therapy

Current Medicinal Chemistry

Volumn 22, Issue 25, 2015, Pages 2991-3012

  Pisonero Vaquero, Sandra ^a   Gonzalez Gallego, Javier ^a,b   Sanchez Campos, Sonia ^a,b   Garcia Mediavilla, Maria Victoria ^a,b  

^a UNIVERSITY OF LEÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antioxidant; Flavonoids; Insulin resistance; Lipid accumulation; Nafld; Quercetin

Indexed keywords

ANTHOCYANIDIN DERIVATIVE; APIGENIN DERIVATIVE; CATECHIN; CHRYSIN; CURCUMIN; CYANIDIN 3 O BETA GLUCOSIDE; EPICATECHIN; EPIGALLOCATECHIN GALLATE; FLAVANGENOL; FLAVANOL DERIVATIVE; FLAVONOID; FLAVONOL DERIVATIVE; GALANGIN; HESPERETIN; ISOFLAVONE DERIVATIVE; ISORHAMNETIN; KAEMPFEROL DERIVATIVE; LIVER PROTECTIVE AGENT; LUTEOLIN; MORIN; NARINGENIN; NATURAL PRODUCT; QUERCETIN DERIVATIVE; RESVERATROL; RUTOSIDE DERIVATIVE; SILIBININ; SILYMARIN; TAXIFOLIN; THEAFLAVIN; UNCLASSIFIED DRUG; PLANT MEDICINAL PRODUCT;

ADIPOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; DISEASE COURSE; DRUG EFFECT; FATTY ACID OXIDATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; LIPID STORAGE; LIPOGENESIS; LIVER PROTECTION; MEDICINAL PLANT; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; SILYBUM MARIANUM; ANIMAL; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; FLAVONOIDS; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; PLANT PREPARATIONS;

EID: 84942155235     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150805094940     Document Type: Article

References (139)

1. Vernon, G.; Baranova, A.; Younossi, Z. M. Systematic review: The epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther., 2011, 34, 274-285.
2. Machado, M.; Cortez-Pinto, H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr. Opin. Clin. Nutr. Metab. Care, 2006, 9, 637-642.
3. Tiniakos, D. G.; Vos, M. B.; Brunt, E. M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol., 2010, 5, 145-171.
4. Tilg, H.; Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology, 2010, 52, 1836-1846.
5. Farrell, G. C.; Larter, C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 2006, 43, S99-S112.
6. Koo, S. H. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin. Mol. Hepatol., 2013, 19, 210-215.
7. Neuschwander-Tetri, B. A. Nontriglyceride hepatic lipotoxicity: The new paradigm for the pathogenesis of NASH. Curr. Gastroenterol. Rep., 2010, 12, 49-56.
8. Miquilena-Colina, M. E.; Lima-Cabello, E.; Sanchez- Campos, S.; Garcia-Mediavilla, M. V.; Fernandez-Bermejo, M.; Lozano-Rodriguez, T.; Vargas-Castrillon, J.; Buque, X.; Ochoa, B.; Aspichueta, P.; Gonzalez-Gallego, J.; Garcia- Monzon, C. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut, 2011, 60, 1394-1402.
9. Lima-Cabello, E.; Garcia-Mediavilla, M. V.; Miquilena- Colina, M. E.; Vargas-Castrillon, J.; Lozano-Rodriguez, T.; Fernandez-Bermejo, M.; Olcoz, J. L.; Gonzalez-Gallego, J.; Garcia- Monzon, C.; Sanchez-Campos, S. Enhanced expression of pro-inflammatory mediators and liver Xreceptor- regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin. Sci. (Lond.), 2011, 120, 239-250.
10. Garcia-Mediavilla, M. V.; Pisonero-Vaquero, S.; Lima- Cabello, E.; Benedicto, I.; Majano, P. L.; Jorquera, F.; Gonzalez- Gallego, J.; Sanchez-Campos, S. Liver X receptor alpha- mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Lab. Invest., 2012, 92, 1191-1202.
11. Uyeda, K.; Repa, J. J. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell. Metab., 2006, 4, 107-110.
12. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20, 649-688.
13. Hussain, M. M.; Shi, J.; Dreizen, P. Microsomal triglyceride transfer protein and its role in apoB- lipoprotein assembly. J. Lipid Res., 2003, 44, 22-32.
14. Torres, D. M.; Harrison, S. A. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology, 2008, 134, 1682-1698.
15. Gonzalez-Gallego, J.; Garcia-Mediavilla, M. V.; Sanchez- Campos, S.; Tunon, M. J. Fruit polyphenols, immunity and inflammation. Br. J. Nutr., 2010, 104(Suppl 3), S15-S27.
16. Ying, H. Z.; Liu, Y. H.; Yu, B.; Wang, Z. Y.; Zang, J. N.; Yu, C. H. Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem. Toxicol., 2013, 52, 53-60.
17. Pisonero-Vaquero, S.; Garcia-Mediavilla, M. V.; Jorquera, F.; Majano, P. L.; Benet, M.; Jover, R.; Gonzalez-Gallego, J.; Sanchez-Campos, S. Modulation of PI3K-LXRalphadependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin. Lab. Invest., 2014, 94, 262-274.
18. Blade, C.; Baselga-Escudero, L.; Salvado, M. J.; Arola- Arnal, A. miRNAs, polyphenols, and chronic disease. Mol. Nutr. Food Res., 2013, 57, 58-70.
19. Eslamparast, T.; Eghtesad, S.; Hekmatdoost, A.; Poustchi, H. Probiotics and nonalcoholic fatty liver disease. Middle East. J. Dig. Dis., 2013, 5, 129-136.
20. Kawabata, K.; Sugiyama, Y.; Sakano, T.; Ohigashi, H. Flavonols enhanced production of anti- inflammatory substance( s) by Bifidobacterium adolescentis: prebiotic actions of galangin, quercetin, and fisetin. Biofactors, 2013, 39, 422-429.
21. Marcolin, E.; San-Miguel, B.; Vallejo, D.; Tieppo, J.; Marroni, N.; Gonzalez-Gallego, J.; Tunon, J. Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J. Nutr., 2012, 142, 1821- 1828.
22. Crespo, I.; Garcia-Mediavilla, M. V.; Almar, M.; Gonzalez, P.; Tunon, M. J.; Sanchez-Campos, S.; Gonzalez-Gallego, J. Differential effects of dietary flavonoids on reactive oxygen and nitrogen species generation and changes in antioxidant enzyme expression induced by proinflammatory cytokines in Chang Liver cells. Food Chem. Toxicol., 2008, 46, 1555-1569.
23. Tieppo, J.; Cuevas, M. J.; Vercelino, R.; Tunon, M. J.; Marroni, N. P.; Gonzalez-Gallego, J. Quercetin administration ameliorates pulmonary complications of cirrhosis in rats. J. Nutr., 2009, 139, 1339-1346.
24. de David, C.; Rodrigues, G.; Bona, S.; Meurer, L.; Gonzalez- Gallego, J.; Tunon, M. J.; Marroni, P. Role of quercetin in preventing thioacetamide-induced liver injury in rats. Toxicol. Pathol., 2011, 39, 949-957.
25. Surapaneni, K. M.; Jainu, M. Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in non alcoholic steatohepatitis. Pharmacognosy Res., 2014, 6, 153- 162.
26. Surapaneni, K. M.; Priya, V. V.; Mallika, J. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH). Eur. Rev. Med. Pharmacol. Sci., 2014, 18, 2736-2741.
27. Li, X.; Wang, R.; Zhou, N.; Wang, X.; Liu, Q.; Bai, Y.; Bai, Y.; Liu, Z.; Yang, H.; Zou, J.; Wang, H.; Shi, T. Quercetin improves insulin resistance and hepatic lipid accumulation in a NAFLD cell model. Biomed. Rep., 2013, 1, 71-76.
28. Vidyashankar, S.; Sandeep Varma, R.; Patki, P. S. Quercetin ameliorate insulin resistance and up- regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells. Toxicol. In Vitro, 2013, 27, 945-953.
29. Panchal, S. K.; Poudyal, H.; Brown, L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in dietinduced metabolic syndrome in rats. J. Nutr., 2012, 142, 1026-1032.
30. Jung, C. H.; Cho, I.; Ahn, J.; Jeon, T. I.; Ha, T. Y. Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. Phytother. Res., 2013, 27, 139-143.
31. Zhang, M. H.; Liang, Z. Q.; Qin, Q.; Li, S. L.; Zhou, D. S.; Tang, L. Effects of quercetin on serum levels of resistin and IL-18 and on insulin resistance in nonalcoholic fatty liver disease rats. Zhonghua Gan Zang Bing Za Zhi, 2013, 21, 66-70.
32. Wang, W.; Wang, C.; Ding, X. Q.; Pan, Y.; Gu, T. T.; Wang, M. X.; Liu, Y. L.; Wang, F. M.; Wang, S. J.; Kong, L. D. Quercetin and allopurinol reduce liver thioredoxininteracting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br. J. Pharmacol., 2013, 169, 1352- 1371.
33. Zhang, D.; Xie, L.; Jia, G.; Cai, S.; Ji, B.; Liu, Y.; Wu, W.; Zhou, F.; Wang, A.; Chu, L.; Wei, Y.; Liu, J.; Gao, F. Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro. Eur. J. Med. Chem., 2011, 46, 4548-4558.
34. Zhou, D. S.; Liang, Z. Q.; Qin, Q.; Zhang, M. H.; Li, S. L. Therapeutic efficacy and mechanisms of quercetin in a rat model of nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi, 2013, 21, 134-137.
35. Das, N.; Sikder, K.; Bhattacharjee, S.; Majumdar, S. B.; Ghosh, S.; Majumdar, S.; Dey, S. Quercetin alleviates inflammation after short-term treatment in high-fat-fed mice. Food Funct., 2013, 4, 889-898.
36. Wang, X.; Zhang, D. M.; Gu, T. T.; Ding, X. Q.; Fan, C. Y.; Zhu, Q.; Shi, Y. W.; Hong, Y.; Kong, L. D. Morin reduces hepatic inflammation-associated lipid accumulation in high fructose-fed rats via inhibiting sphingosine kinase 1/sphingosine 1-phosphate signaling pathway. Biochem. Pharmacol., 2013, 86, 1791-1804.
37. Panchal, S. K.; Poudyal, H.; Arumugam, T. V.; Brown, L. Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J. Nutr., 2011, 141, 1062-1069.
38. Zhang, Z. F.; Fan, S. H.; Zheng, Y. L.; Lu, J.; Wu, D. M.; Shan, Q.; Hu, B. Troxerutin improves hepatic lipid homeostasis by restoring NAD(+)-depletion-mediated dysfunction of lipin 1 signaling in high-fat diet-treated mice. Biochem. Pharmacol., 2014, 91, 74-86.
39. Li, X. Y.; Kong, L. X.; Li, J.; He, H. X.; Zhou, Y. D. Kaempferol suppresses lipid accumulation in macrophages through the downregulation of cluster of differentiation 36 and the upregulation of scavenger receptor class B type I and ATP-binding cassette transporters A1 and G1. Int. J. Mol. Med., 2013, 31, 331-338.
40. Zhang, N.; Pei, F.; Wei, H.; Zhang, T.; Yang, C.; Ma, G.; Yang, C. Isorhamnetin protects rat ventricular myocytes from ischemia and reperfusion injury. Exp. Toxicol. Pathol. 2011, 63, 33-38.
41. Kong, C. S.; Seo, Y. Antiadipogenic activity of isohamnetin 3-O-beta-D-glucopyranoside from Salicornia herbacea. Immunopharmacol. Immunotoxicol., 2012, 34, 907-911.
42. Ramachandran, L.; Manu, K. A.; Shanmugam, M. K.; Li, F.; Siveen, K. S.; Vali, S.; Kapoor, S.; Abbasi, T.; Surana, R.; Smoot, D. T.; Ashktorab, H.; Tan, P.; Ahn, K. S.; Yap, C. W.; Kumar, A. P.; Sethi, G. Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor gamma activation pathway in gastric cancer. J. Biol. Chem., 2012, 287, 38028-38040.
43. Chirumbolo, S. Anti-inflammatory action of isorhamnetin. Inflammation, 2014, 37, 1200-1201.
44. Dong, G. Z.; Lee, J. H.; Ki, S. H.; Yang, J. H.; Cho, I. J.; Kang, S. H.; Zhao, R. J.; Kim, S. C.; Kim, Y. W. AMPK activation by isorhamnetin protects hepatocytes against oxidative stress and mitochondrial dysfunction. Eur. J. Pharmacol., 2014, 740, 634-640.
45. Choi, H. N.; Kang, M. J.; Lee, S. J.; Kim, J. I. Ameliorative effect of myricetin on insulin resistance in mice fed a highfat, high-sucrose diet. Nutr. Res. Pract., 2014, 8, 544-549.
46. Chang, C. J.; Tzeng, T. F.; Liou, S. S.; Chang, Y. S.; Liu, I. M. Myricetin increases hepatic peroxisome proliferatoractivated receptor alpha protein expression and decreases plasma lipids and adiposity in rats. Evid. Based. Complement. Alternat. Med., 2012, 2012, 787152.
47. Jung, C. H.; Jang, S. J.; Ahn, J.; Gwon, S. Y.; Jeon, T. I.; Kim, T. W.; Ha, T. Y. Alpinia officinarum inhibits adipocyte differentiation and high-fat diet-induced obesity in mice through regulation of adipogenesis and lipogenesis. J. Med. Food, 2012, 15, 959-967.
48. Jiang, Y.; Gong, F. L.; Zhao, G. B.; Li, J. Chrysin suppressed inflammatory responses and the inducible nitric ox ide synthase pathway after spinal cord injury in rats. Int. J. Mol. Sci., 2014, 15, 12270-12279.
49. Yang, B.; Huang, J.; Xiang, T.; Yin, X.; Luo, X.; Huang, J.; Luo, F.; Li, H.; Li, H.; Ren, G. Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway. J. Appl. Toxicol., 2014, 34, 105-112.
50. Sirovina, D.; Orsolic, N.; Koncic, M. Z.; Kovacevic, G.; Benkovic, V.; Gregorovic, G. Quercetin vs chrysin: effect on liver histopathology in diabetic mice. Hum. Exp. Toxicol., 2013, 32, 1058- 1066.
51. Liang, Y. C.; Tsai, S. H.; Tsai, D. C.; Lin-Shiau, S. Y.; Lin, J. K. Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator- Activated receptor-gamma by flavonoids in mouse macrophages. FEBS Lett., 2001, 496, 12-18.
52. Feng, X.; Qin, H.; Shi, Q.; Zhang, Y.; Zhou, F.; Wu, H.; Ding, S.; Niu, Z.; Lu, Y.; Shen, P. Chrysin attenuates inflammation by regulating M1/M2 status via activating PPARgamma. Biochem. Pharmacol., 2014, 89, 503-514.
53. Wang, J.; Liu, Y. T.; Xiao, L.; Zhu, L.; Wang, Q.; Yan, T. Anti-inflammatory effects of apigenin in lipopolysaccharide- induced inflammatory in acute lung injury by suppressing COX-2 and NF- kB pathway. Inflammation, 2014, 37(16), 2085-2090.
54. Zhang, X.; Wang, G.; Gurley, E. C.; Zhou, H. Flavonoid apigenin inhibits lipopolysaccharide- induced inflammatory response through multiple mechanisms in macrophages. PLoS One, 2014, 9, e107072.
55. Tong, X.; Pelling, J. C. Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. Anticancer Agents Med. Chem., 2013, 13, 971-978.
56. Bao, Y. Y.; Zhou, S. H.; Fan, J.; Wang, Q. Y. Anticancer mechanism of apigenin and the implications of GLUT-1 expression in head and neck cancers. Future Oncol. 2013, 9, 1353-1364.
57. Lefort, E. C.; Blay, J. Apigenin and its impact on gastrointestinal cancers. Mol. Nutr. Food Res., 2013, 57, 126-144.
58. Bumke-Vogt, C.; Osterhoff, M. A.; Borchert, A.; Guzman- Perez, V.; Sarem, Z.; Birkenfeld, A. L.; Bahr, V.; Pfeiffer, A. F. The flavones apigenin and luteolin induce FOXO1 translocation but inhibit gluconeogenic and lipogenic gene expression in human cells. PLoS One 2014, 9, e104321.
59. Lopez-Lazaro, M. Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem., 2009, 9, 31- 59.
60. Chen, D.; Bi, A.; Dong, X.; Jiang, Y.; Rui, B.; Liu, J.; Yin, Z.; Luo, L. Luteolin exhibits anti- inflammatory effects by blocking the activity of heat shock protein 90 in macrophages. Biochem. Biophys. Res. Commun., 2014, 443, 326- 332.
61. Kim, Y. S.; Kim, S. H.; Shin, J.; Harikishore, A.; Lim, J. K.; Jung, Y.; Lyu, H. N.; Baek, N. I.; Choi, K. Y.; Yoon, H. S.; Kim, K. T. Luteolin suppresses cancer cell proliferation by targeting vaccinia-related kinase 1. PLoS One, 2014, 9, e109655.
62. Osman, N. H.; Said, U. Z.; El-Waseef, A. M.; Ahmed, E. S. Luteolin supplementation adjacent to aspirin treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats. Tumour Biol., 2014.
63. Liu, J. F.; Ma, Y.; Wang, Y.; Du, Z. Y.; Shen, J. K.; Peng, H. L. Reduction of lipid accumulation in HepG2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress. Phytother. Res., 2011, 25, 588-596.
64. Mulvihill, E. E.; Allister, E. M.; Sutherland, B. G.; Telford, D. E.; Sawyez, C. G.; Edwards, J. Y.; Markle, J. M.; Hegele, R. A.; Huff, M. W. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes, 2009, 58, 2198-2210.
65. Esmaeili, A. H.; Hajizadeh Moghaddam, A.; Chaichi, M. J. Identification, determination, and study of antioxidative activities of hesperetin and gallic acid in hydro-alcoholic extract from flowers of Eriobotrya japonica (Lindl.). Avicenna J. Phytomed, 2014, 4, 260-266.
66. Fordham, J. B.; Naqvi, A. R.; Nares, S. Leukocyte production of inflammatory mediators is inhibited by the antioxidants phloretin, silymarin, hesperetin, and resveratrol. Mediators Inflamm., 2014, 2014, 938712.
67. Palit, S.; Kar, S.; Sharma, G.; Das, P. K. Hesperetin induces apoptosis in breast carcinoma by triggering accumulation of ROS and activation of ASK1/JNK pathway. J. Cell. Physiol., 2014, 230(8), 1729-1739.
68. Lee, N. K.; Choi, S. H.; Park, S. H.; Park, E. K.; Kim, D. H. Antiallergic activity of hesperidin is activated by intestinal microflora. Pharmacology, 2004, 71, 174-180.
69. Choi, E. J.; Ahn, W. S. Neuroprotective effects of chronic hesperetin administration in mice. Arch. Pharm. Res., 2008, 31, 1457-1462.
70. Casaschi, A.; Rubio, B. K.; Maiyoh, G. K.; Theriault, A. G. Inhibitory activity of diacylglycerol acyltransferase (DGAT) and microsomal triglyceride transfer protein (MTP) by the flavonoid, taxifolin, in HepG2 cells: potential role in the regulation of apolipoprotein B secretion. Atherosclerosis, 2004, 176, 247-253.
71. Brusselmans, K.; Vrolix, R.; Verhoeven, G.; Swinnen, J. V. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J. Biol. Chem., 2005, 280, 5636-5645.
72. Kochi, T.; Shimizu, M.; Terakura, D.; Baba, A.; Ohno, T.; Kubota, M.; Shirakami, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions. Cancer Lett., 2014, 342, 60-69.
73. Xiao, J.; Ho, C. T.; Liong, E. C.; Nanji, A. A.; Leung, T. M.; Lau, T. Y.; Fung, M. L.; Tipoe, G. L. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur. J. Nutr., 2014, 53, 187-199.
74. Shimada, T.; Tokuhara, D.; Tsubata, M.; Kamiya, T.; Kamiya- Sameshima, M.; Nagamine, R.; Takagaki, K.; Sai, Y.; Miyamoto, K.; Aburada, M. Flavangenol (pine bark extract) and its major component procyanidin B1 enhance fatty acid oxidation in fat-loaded models. Eur. J. Pharmacol., 2012, 677, 147-153.
75. Kim, M. H.; Kang, K. S. Isoflavones as a smart curer for non-alcoholic fatty liver disease and pathological adiposity via ChREBP and Wnt signaling. Prev. Med., 2012, 54(Suppl), S57-S63.
76. Westmark, C. J. A hypothesis regarding the molecular mechanism underlying dietary soy-induced effects on seizure propensity. Front. Neurol., 2014, 5, 169.
77. Kim, M. H.; Park, J. S.; Jung, J. W.; Byun, K. W.; Kang, K. S.; Lee, Y. S. Daidzein supplementation prevents nonalcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism. Int. J. Obes. (Lond.), 2011, 35, 1019-1030.
78. Zheng, P. Y.; Ma, Z. S.; Hua, Y. Q.; Liu, T.; Xing, L. J.; Ji, G. Effects of puerarin on expressions of leptin receptor mRNA, phosphorylated Janus kinase 2/phosphorylated signal transducers and activators of transcription 3 proteins in the liver of rats with non-alcoholic fatty liver. Zhong Xi Yi Jie He Xue Bao, 2008, 6, 921-927.
79. Zheng, P.; Ji, G.; Ma, Z.; Liu, T.; Xin, L.; Wu, H.; Liang, X.; Liu, J. Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways. Am. J. Chin. Med., 2009, 37, 69-83.
80. Wang, Y.; Li, J.; Zhuge, L.; Su, D.; Yang, M.; Tao, S.; Li, J. Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- And choline-deficient diet. Exp. Ther. Med., 2014, 7, 663-668.
81. Mohamed Salih, S.; Nallasamy, P.; Muniyandi, P.; Periyasami, V.; Carani Venkatraman, A. Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance. J. Diabetes, 2009, 1, 278-287.
82. Kim, M. H.; Kang, K. S.; Lee, Y. S. The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease. Br. J. Nutr., 2010, 104, 1333-1342.
83. Shih, P. H.; Hwang, S. L.; Yeh, C. T.; Yen, G. C. Synergistic effect of cyanidin and PPAR agonist against nonalcoholic steatohepatitis-mediated oxidative stress-induced cytotoxicity through MAPK and Nrf2 transduction pathways. J. Agric. Food Chem., 2012, 60, 2924-2933.
84. Wei, X.; Wang, D.; Yang, Y.; Xia, M.; Li, D.; Li, G.; Zhu, Y.; Xiao, Y.; Ling, W. Cyanidin-3-O- beta-glucoside improves obesity and triglyceride metabolism in KK-Ay mice by regulating lipoprotein lipase activity. J. Sci. Food Agric., 2011, 91, 1006-1013.
85. Guo, H.; Li, D.; Ling, W.; Feng, X.; Xia, M. Anthocyanin inhibits high glucose-induced hepatic mtGPAT1 activation and prevents fatty acid synthesis through PKCzeta. J. Lipid Res., 2011, 52, 908-922.
86. Jiang, X.; Tang, X.; Zhang, P.; Liu, G.; Guo, H. Cyanidin- 3-O-beta-glucoside protects primary mouse hepatocytes against high glucose-induced apoptosis by modulating mitochondrial dysfunction and the PI3K/Akt pathway. Biochem. Pharmacol., 2014, 90, 135-144.
87. Wu, T.; Qi, X.; Liu, Y.; Guo, J.; Zhu, R.; Chen, W.; Zheng, X.; Yu, T. Dietary supplementation with purified mulberry (Morus australis Poir) anthocyanins suppresses body weight gain in high- fat diet fed C57BL/6 mice. Food Chem., 2013, 141, 482-487.
88. Valenti, L.; Riso, P.; Mazzocchi, A.; Porrini, M.; Fargion, S.; Agostoni, C. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. Oxid. Med. Cell. Longev., 2013, 2013, 145421.
89. Mao, Z. M.; Song, H. Y.; Yang, L. L.; Liu, T.; Li, D. F.; Zheng, P. Y.; Liu, P.; Ji, G. Effects of the mixture of Swertia pseudochinensis Hara and Silybum marianum Gaertn extracts on CCl(4)- induced liver injury in rats with nonalcoholic fatty liver disease. Zhong Xi Yi Jie He Xue Bao, 2012, 10, 193-199.
90. Zhang, S.; Zheng, L.; Dong, D.; Xu, L.; Yin, L.; Qi, Y.; Han, X.; Lin, Y.; Liu, K.; Peng, J. Effects of flavonoids from Rosa laevigata Michx fruit against high-fat dietinduced non-alcoholic fatty liver disease in rats. Food Chem., 2013, 141, 2108-2116.
91. Salamone, F.; Galvano, F.; Cappello, F.; Mangiameli, A.; Barbagallo, I.; Li Volti, G. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl. Res., 2012, 159, 477-486.
92. Salamone, F.; Galvano, F.; Marino Gammazza, A.; Paternostro, C.; Tibullo, D.; Bucchieri, F.; Mangiameli, A.; Parola, M.; Bugianesi, E.; Li Volti, G. Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Dig. Liver Dis., 2012, 44, 334-342.
93. Yao, J.; Zhi, M.; Minhu, C. Effect of silybin on high-fatinduced fatty liver in rats. Braz. J. Med. Biol. Res., 2011, 44, 652-659.
94. Li, Z. Z.; Berk, M.; McIntyre, T. M.; Feldstein, A. E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J. Biol. Chem., 2009, 284, 5637-5644.
95. Guzman, C.; Benet, M.; Pisonero-Vaquero, S.; Moya, M.; Garcia-Mediavilla, M. V.; Martinez- Chantar, M. L.; Gonzalez- Gallego, J.; Castell, J. V.; Sanchez-Campos, S.; Jover, R. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARalpha; and repressed by C/EBPalpha: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochim. Biophys. Acta, 2013, 1831, 803-818.
96. Aghazadeh, S.; Amini, R.; Yazdanparast, R.; Ghaffari, S. H. Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis. Exp. Toxicol. Pathol., 2011, 63, 569-574.
97. Kim, M.; Yang, S. G.; Kim, J. M.; Lee, J. W.; Kim, Y. S.; Lee, J. I. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: Analysis of isolated hepatic stellate cells. Int. J. Mol. Med., 2012, 30, 473-479.
98. Buturova, L. I.; Tsybizova, T. A.; Kalinin, A. V. Use of Legalon in non-alcoholic fatty liver disease. Eksp. Klin. Gastroenterol., 2010, (5), 69-75.
99. Cacciapuoti, F.; Scognamiglio, A.; Palumbo, R.; Forte, R.; Cacciapuoti, F. Silymarin in non alcoholic fatty liver disease. World J. Hepatol., 2013, 5, 109-113.
100. Schrieber, S. J.; Hawke, R. L.; Wen, Z.; Smith, P. C.; Reddy, K. R.; Wahed, A. S.; Belle, S. H.; Afdhal, N. H.; Navarro, V. J.; Meyers, C. M.; Doo, E.; Fried, M. W. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab. Dispos., 2011, 39, 2182-2190.
101. Kidd, P. M. Bioavailability and activity of phytosome complexes from botanical polyphenols: The silymarin, curcumin, green tea, and grape seed extracts. Altern. Med. Rev., 2009, 14, 226-246.
102. Loguercio, C.; Andreone, P.; Brisc, C.; Brisc, M. C.; Bugianesi, E.; Chiaramonte, M.; Cursaro, C.; Danila, M.; de Sio, I.; Floreani, A.; Freni, M. A.; Grieco, A.; Groppo, M.; Lazzari, R.; Lobello, S.; Lorefice, E.; Margotti, M.; Miele, L.; Milani, S.; Okolicsanyi, L.; Palasciano, G.; Portincasa, P.; Saltarelli, P.; Smedile, A.; Somalvico, F.; Spadaro, A.; Sporea, I.; Sorrentino, P.; Vecchione, R.; Tuccillo, C.; Del Vecchio Blanco, C.; Federico, A. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic. Biol. Med., 2012, 52, 1658-1665.
103. Iakimchuk, G. N.; Gendrikson, L. N. Study of clinical efficiency of essential phospholipids and silymarin combination in nonalcoholic and alcoholic steatohepatitis. Eksp. Klin. Gastroenterol., 2011, (7), 64-69.
104. Federico, A.; Trappoliere, M.; Tuccillo, C.; de Sio, I.; Di Leva, A.; Del Vecchio Blanco, C.; Loguercio, C. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut, 2006, 55, 901-902.
105. Trappoliere, M.; Federico, A.; Tuccillo, C.; de Sio, I.; Di Leva, A.; Niosi, M.; D'Auria, M.; Loguercio, C.; Real Sud Group 2 Effects of a new pharmacological complex (silybin + vitamin-E + phospholipids) on some markers of the metabolic syndrome and of liver fibrosis in patients with hepatic steatosis. Preliminary study. Minerva Gastroenterol. Dietol., 2005, 51, 193-199.
106. Zeng, C. H.; Zeng, P.; Deng, Y. H.; Shen, N.; Peng, M. L.; Liu, Q.; Ren, H. The effects of curcumin derivative on experimental steatohepatitis. Zhonghua Gan Zang Bing Za Zhi, 2011, 19, 454-459.
107. Kuo, J. J.; Chang, H. H.; Tsai, T. H.; Lee, T. Y. Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis. Int. J. Mol. Med., 2012, 30, 673-679.
108. Kang, O. H.; Kim, S. B.; Seo, Y. S.; Joung, D. K.; Mun, S. H.; Choi, J. G.; Lee, Y. M.; Kang, D. G.; Lee, H. S.; Kwon, D. Y. Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells. Eur. Rev. Med. Pharmacol. Sci., 2013, 17, 2578-2586.
109. Kuo, J. J.; Chang, H. H.; Tsai, T. H.; Lee, T. Y. Curcumin ameliorates mitochondrial dysfunction associated with inhibition of gluconeogenesis in free fatty acid-mediated hepatic lipoapoptosis. Int. J. Mol. Med., 2012, 30, 643-649.
110. Messner, D. J.; Rhieu, B. H.; Kowdley, K. V. Iron overload causes oxidative stress and impaired insulin signaling in AML-12 hepatocytes. Dig. Dis. Sci., 2013, 58, 1899-1908.
111. Zhu, W.; Chen, S.; Li, Z.; Zhao, X.; Li, W.; Sun, Y.; Zhang, Z.; Ling, W.; Feng, X. Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice. Nutr. Metab. (Lond.), 2014, 11, 35.
112. Aguirre, L.; Portillo, M. P.; Hijona, E.; Bujanda, L. Effects of resveratrol and other polyphenols in hepatic steatosis. World J. Gastroenterol., 2014, 20, 7366-7380.
113. Aoun, M.; Michel, F.; Fouret, G.; Casas, F.; Jullien, M.; Wrutniak-Cabello, C.; Ramos, J.; Cristol, J. P.; Coudray, C.; Carbonneau, M. A.; Feillet-Coudray, C. A polyphenol extract modifies quantity but not quality of liver fatty acid content in high-fat-high-sucrose diet-fed rats: possible implication of the sirtuin pathway. Br. J. Nutr., 2010, 104, 1760-1770.
114. Panchal, S. K.; Brown, L. Cardioprotective and hepatoprotective effects of ellagitannins from European oak bark (Quercus petraea L.) extract in rats. Eur. J. Nutr., 2013, 52, 397-408.
115. Luo, X. Y.; Takahara, T.; Hou, J.; Kawai, K.; Sugiyama, T.; Tsukada, K.; Takemoto, M.; Takeuchi, M.; Zhong, L.; Li, X. K. Theaflavin attenuates ischemia-reperfusion injury in a mouse fatty liver model. Biochem. Biophys. Res. Commun., 2012, 417, 287-293.
116. Chung, M. Y.; Park, H. J.; Manautou, J. E.; Koo, S. I.; Bruno, R. S. Green tea extract protects against nonalcoholic steatohepatitis in ob/ob mice by decreasing oxidative and nitrative stress responses induced by proinflammatory enzymes. J. Nutr. Biochem., 2012, 23, 361-367.
117. Park, H. J.; Lee, J. Y.; Chung, M. Y.; Park, Y. K.; Bower, A. M.; Koo, S. I.; Giardina, C.; Bruno, R. S. Green tea extract suppresses NFkappaB activation and inflammatory responses in diet- induced obese rats with nonalcoholic steatohepatitis. J. Nutr., 2012, 142, 57-63.
118. Sakata, R.; Nakamura, T.; Torimura, T.; Ueno, T.; Sata, M. Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: A double-blind placebo-controlled study. Int. J. Mol. Med., 2013, 32, 989-994.
119. Masterjohn, C.; Bruno, R. S. Therapeutic potential of green tea in nonalcoholic fatty liver disease. Nutr. Rev., 2012, 70, 41-56.
120. Jung, J. H.; Kim, H. S. The inhibitory effect of black soybean on hepatic cholesterol accumulation in high cholesterol and high fat diet-induced non-alcoholic fatty liver disease. Food Chem. Toxicol., 2013, 60, 404-412.
121. Badger, T. M.; Ronis, M. J.; Wolff, G.; Stanley, S.; Ferguson, M.; Shankar, K.; Simpson, P.; Jo, C. H. Soy protein isolate reduces hepatosteatosis in yellow Avy/a mice without altering coat color phenotype. Exp. Biol. Med. (Maywood), 2008, 233, 1242-1254.
122. Leng, L.; Jiang, Z. Q.; Ji, G. Y. Effects of soybean isoflavone on liver lipid metabolism in nonalcoholic fatty liver rats. Zhonghua Yu Fang Yi Xue Za Zhi, 2011, 45, 335-339.
123. Davaatseren, M.; Hur, H. J.; Yang, H. J.; Hwang, J. T.; Park, J. H.; Kim, H. J.; Kim, M. J.; Kwon, D. Y.; Sung, M. J. Taraxacum official (dandelion) leaf extract alleviates high-fat diet-induced nonalcoholic fatty liver. Food Chem. Toxicol., 2013, 58, 30-36.
124. Davaatseren, M.; Hur, H. J.; Yang, H. J.; Hwang, J. T.; Park, J. H.; Kim, H. J.; Kim, M. S.; Kim, M. J.; Kwon, D. Y.; Sung, M. J. Dandelion leaf extract protects against liver injury induced by methionine- And choline-deficient diet in mice. J. Med. Food, 2013, 16, 26-33.
125. Vareda, P. M.; Saldanha, L. L.; Camaforte, N. A.; Violato, N. M.; Dokkedal, A. L.; Bosqueiro, J. R. Myrcia bella leaf extract presents hypoglycemic activity via PI3k/Akt insulin signaling pathway. Evid. Based Complement. Alternat. Med., 2014, 2014, 543606.
126. Shen, B.; Yu, J.; Wang, S.; Chu, E. S.; Wong, V. W.; Zhou, X.; Lin, G.; Sung, J. J.; Chan, H. L. Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. Hepatology, 2008, 47, 473-483.
127. Yang, J.; Lv, F.; Chen, X. Q.; Cui, W. X.; Chen, L. H.; Wen, X. D.; Wang, Q. Pharmacokinetic study of major bioactive components in rats after oral administration of extract of Ilex hainanensis by high-performance liquid chromatography/electrospray ionization mass spectrometry. J. Pharm. Biomed. Anal., 2013, 77, 21-28.
128. Cui, W. X.; Yang, J.; Chen, X. Q.; Mao, Q.; Wei, X. L.; Wen, X. D.; Wang, Q. Triterpenoid-rich fraction from Ilex hainanensis Merr. attenuates non-alcoholic fatty liver disease induced by high fat diet in rats. Am. J. Chin. Med., 2013, 41, 487-502.
129. Li, J. J.; Yang, J.; Cui, W. X.; Chen, X. Q.; Chen, G. L.; Wen, X. D.; Wang, Q. Analysis of therapeutic effect of Ilex hainanensis Merr. extract on nonalcoholic fatty liver disease through urine metabolite profiling by ultraperformance liquid chromatography/quadrupole time of flight mass spectrometry. Evid. Based Complement. Alternat. Med., 2013, 2013, 451975.
130. Wang, S. D.; Xie, Z. Q.; Chen, J.; Wang, K.; Wei, T.; Zhao, A. H.; Zhang, Q. H. Inhibitory effect of Ginkgo biloba extract on fatty liver: regulation of carnitine palmitoyltransferase 1a and fatty acid metabolism. J. Dig. Dis., 2012, 13, 525-535.
131. Wei, T.; Xiong, F. F.; Wang, S. D.; Wang, K.; Zhang, Y. Y.; Zhang, Q. H. Flavonoid ingredients of. J. Biomed. Sci., 2014, 21, 87.
132. Zhang, L.; Xu, J.; Song, H.; Yao, Z.; Ji, G. Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity. J. Transl. Med., 2014, 12, 236.
133. Yin, J.; Luo, Y.; Deng, H.; Qin, S.; Tang, W.; Zeng, L.; Zhou, B. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARalpha pathways in L02 cells and HepG2 cells. J. Ethnopharmacol., 2014, 154, 229-239.
134. Chen, Z. Y.; Li, J. S.; Jiang, J. P.; Yan, M. X.; He, B. H. Effect of pure total flavonoids from citrus on hepatic SIRT1/PGC-1alpha pathway in mice with NASH. Zhongguo Zhong Yao Za Zhi, 2014, 39, 100-105.
135. Wei, Y. Y.; Yan, D.; Japar, A.; Qu, S. S.; Haji, A. A.; Parhat, K. Effects of pomegranate flowers polyphenols on liver PON expression of diabetes combining non-alcoholic fat liver diseases rats. Yao Xue Xue Bao, 2013, 48, 71-76.
136. Liu, Y.; Wang, D.; Zhang, D.; Lv, Y.; Wei, Y.; Wu, W.; Zhou, F.; Tang, M.; Mao, T.; Li, M.; Ji, B. Inhibitory effect of blueberry polyphenolic compounds on oleic acid-induced hepatic steatosis in vitro. J. Agric. Food Chem., 2011, 59, 12254-12263.
137. Wu, T.; Tang, Q.; Gao, Z.; Yu, Z.; Song, H.; Zheng, X.; Chen, W. Blueberry and mulberry juice prevent obesity development in C57BL/6 mice. PLoS One, 2013, 8, e77585.
138. Guo, H.; Zhong, R.; Liu, Y.; Jiang, X.; Tang, X.; Li, Z.; Xia, M.; Ling, W. Effects of bayberry juice on inflammatory and apoptotic markers in young adults with features of non-alcoholic fatty liver disease. Nutrition, 2014, 30, 198- 203.
139. Tsuruta, Y.; Nagao, K.; Kai, S.; Tsuge, K.; Yoshimura, T.; Koganemaru, K.; Yanagita, T. Polyphenolic extract of lotus root (edible rhizome of Nelumbo nucifera) alleviates hepatic steatosis in obese diabetic db/db mice. Lipids Health Dis., 2011, 10, 202.